Brief: Acacia Pharma Partners With Cosmo Pharmaceuticals

Cosmo NV

10/01/2020 06:32

Jan 10 (Reuters) - Acacia Pharma Group PLC  ACPH.BR :
    * ACACIA PHARMA ENTERS INTO STRATEGIC IN-LICENSING,
INVESTMENT AND
LOAN TRANSACTION WITH COSMO PHARMACEUTICALS N.V.
    * TRANSACTION GRANTS TO GROUP EXCLUSIVE US COMMERCIALISATION
RIGHTS TO BYFAVO™ (REMIMAZOLAM)
    * A €30 MILLION PAYMENT FROM ACACIA PHARMA UPON US APPROVAL
OF
BYFAVO, CONSISTING OF €15 MILLION PAYABLE IN CASH AND €15
MILLION PAYABLE IN CASH OR NEW ORDINARY SHARES AT ACACIA
PHARMA’S OPTION
    * TRANSACTION HAS BEEN MADE ALONGSIDE AN EQUITY INVESTMENT
AND
DEBT FACILITY BY COSMO TO FINANCE MARKETING EFFORTS OF BOTH
BARHEMSYS® AND BYFAVO

Source text for Eikon:  ID:nGNE4KzgDs 
Further company coverage:  ACPH.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))